These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
177 related items for PubMed ID: 6148467
21. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Menon N, McAlpine L, Peacock AJ, Madhok R. Arthritis Rheum; 1998 Mar; 41(3):466-9. PubMed ID: 9506575 [Abstract] [Full Text] [Related]
26. Primary pulmonary hypertension: Current therapy. Sitbon O, Humbert M, Simonneau G. Prog Cardiovasc Dis; 2002 Mar; 45(2):115-28. PubMed ID: 12411973 [Abstract] [Full Text] [Related]
27. Vasodilators in the treatment of primary pulmonary hypertension. Weir EK, Schremmer B. Eur Respir J; 1998 Aug; 12(2):263-4. PubMed ID: 9727771 [No Abstract] [Full Text] [Related]
28. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Lancet; 2002 Sep 21; 360(9337):895-900. PubMed ID: 12354470 [Abstract] [Full Text] [Related]
29. Outcomes in children with idiopathic pulmonary arterial hypertension. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Circulation; 2004 Aug 10; 110(6):660-5. PubMed ID: 15289375 [Abstract] [Full Text] [Related]
30. The United States experience with the acute and chronic treatment of primary pulmonary hypertension. Weir EK. Eur Heart J; 1988 Sep 10; 9 Suppl J():33-8. PubMed ID: 3053183 [Abstract] [Full Text] [Related]
31. Comparison of acute hemodynamic responses to prostacyclin with standard vasodilators in patients with primary pulmonary hypertension. Palevsky HI, Fishman AP. Chest; 1988 Mar 10; 93(3 Suppl):179S. PubMed ID: 3277819 [No Abstract] [Full Text] [Related]
32. Inhaled nitric oxide potentiates actions of adenosine but not of sodium nitroprusside in experimental pulmonary hypertension. Patterson KW, Deb B, Kavanagh BP, Pearl RG. Pharmacology; 1999 May 10; 58(5):246-51. PubMed ID: 10087465 [Abstract] [Full Text] [Related]
35. The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use. Krasuski RA, Wang A, Harrison JK, Tapson VF, Bashore TM. Am Heart J; 2005 Oct 10; 150(4):725-8. PubMed ID: 16209974 [Abstract] [Full Text] [Related]
36. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Elliott CG, Fishman AP, Goldring RM, Groves BM. Am Rev Respir Dis; 1989 Dec 10; 140(6):1623-30. PubMed ID: 2690706 [Abstract] [Full Text] [Related]
37. Current management of patients with pulmonary hypertension and right ventricular insufficiency. Hankins SR, Horn EM. Curr Cardiol Rep; 2000 May 10; 2(3):244-51. PubMed ID: 10980899 [Abstract] [Full Text] [Related]
38. Vasodilator therapy for primary pulmonary hypertension in children. Barst RJ, Maislin G, Fishman AP. Circulation; 1999 Mar 09; 99(9):1197-208. PubMed ID: 10069788 [Abstract] [Full Text] [Related]
39. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Mayo Clin Proc; 2003 Oct 09; 78(10):1207-13. PubMed ID: 14531479 [Abstract] [Full Text] [Related]